Table 1.
Comparative evaluation of the features between COVID-19 recovered and 120 healthy controls subjects.
| Post COVID-19 patients (n = 92) | Controls (n = 120) | p-value | |
|---|---|---|---|
| Age | 50.6 ± 12.1 | 51.8 ± 4.2 | 0.39 |
| Gender (Male) | 54 (58.7%) | 65 (54.1%) | 0.51 |
| Hypertension | 11 (11.9%) | 10 (8.3%) | 0.37 |
| Mean HR | 88.1 ± 15.2 | 77.6 ± 11.3 | <0.0001 |
| HRV (SDNN) | 16.9 ± 12.9 | 22.5 ± 17.6 | 0.01 |
| HRV (RMSSD) | 13.9 ± 11.8 | 19.9 ± 19.5 | 0.01 |
| Avg signal value (microV) | 0.1 ± 0.3 | 0.1 ± 0.3 | 0.907 |
| Avg RR interval (ms) | 704.3 ± 116.1 | 787.8 ± 110.2 | <0.001 |
| COVID-19 recoveredsubjects' symptoms | |||
| Symptoms during COVID-19 | |||
| Fever | 63 (68.5%) | – | |
| Cough | 50 (54.3%) | – | |
| Sore throat | 16 (17.4%) | – | |
| Dyspnoea | 34 (36.9%) | – | |
| Chest pain | 14 (15.2%) | – | |
| Myalgia | 11 (11.9%) | – | |
| Anosmia/Aguesia | 10 (10.9%) | – | |
| Headache | 4 (4.3%) | – | |
| Symptoms post COVID-19 | 39 (42.4%) | – | |
| Dyspnoea | 16 (17.4%) | – | |
| Cough | 8 (8.7%) | – | |
| Fatigue | 11 (11.9%) | – | |
| Palpitations | 15 (16.3%) | – | |
| Orthostatic intolerance | 14 (15.2%) | – | |
| Chest pain | 11 (11.9%) | – | |
| Dizziness | 13 (14.1%) | – | |
| Syncope | 2 (2.1%) | – | |
| Severity | |||
| Asymptomatic | 12 (13.1%) | – | |
| Mild | 38 (41.3%) | – | |
| Moderate | 32 (34.7%) | – | |
| Severe | 10 (10.9%) | – | |
Abbreviations: Avg: average; HR: heart rate; HRV: Heart rate variability; microV: microvolt; ms: millisecond; RMSSD: Root Mean Square Standard Deviation.